RevBio Receives a $2.4 Million NIH Grant to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation and Enrolls First Five Patients

RevBio, Inc., announced that it has been awarded a $2.4 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disease and Stroke (NINDS), part of the National Institutes of Health (NIH). This two-year grant (1R44NS135736-01A1) will allow the company to complete a 20-patient pilot clinical trial to examine the safety and efficacy of the company’s bone adhesive biomaterial called TETRANITE® which will be used to immediately fixate cranial flaps and enable bone fusion following craniotomy procedures associated with brain surgery. This clinical trial has already been approved by FDA for the stand-alone use of TETRANITE to replace metal plates and screws. The clinical trial is being conducted at the Semmes Murphey Clinic in Memphis, Tennessee, and Brigham and Women’s Hospital in Boston, Massachusetts. The first five patients have already been successfully enrolled, with the first patient having had more than 3-months of healing following the flap closure surgery involving TETRANITE. Read more >>

“